Immutep Limited (IMMP) –
-
Immutep Limited (IMMP) Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
-
Immutep (IMMP) Receives A$2.6 million R&D Tax Incentive from French Government
-
Immutep Receives A$2.6 million R&D Tax Incentive from French Government
-
Immutep receives ~A$1.13 million R&D Tax Incentive
-
Baird Starts Immutep Limited (IMMP) at Outperform, 'Unique LAG-3 Agent with Fast Track Designations'
-
Immutep Receives Positive Scientific Advice from European Medicines Agency
-
Immutep Quarterly Activities Report Q4 FY23
-
Immutep to Present Overall Survival Data in 1st Line Non-Small Cell Lung Cancer Accepted for Oral Presentation at ESMO Congress 2023
-
First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma
-
Immutep Completes A$80 Million Capital Raise
-
Immutep Secures Third United States Patent for Eftilagimod Alpha in Combination with a PD-1 Pathway Inhibitor
-
Immutep (IMM) Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3
-
Immutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3
-
Immutep to Participate at the Jefferies Healthcare Conference
-
Immutep Reports Final Positive Data in 2nd Line Head and Neck Squamous Cell Carcinoma at ASCO 2023 Annual Meeting
-
Immutep Successfully Completes Institutional Placement and Institutional Component of its Entitlement Offer
-
Immutep Limited (IMMP) Halted, News Pending
-
Immutep Selects Charles River Laboratories for IMP761’s GLP Toxicology Study
-
Immutep (IMMP) Announces Publication of Abstracts
-
Immutep Announces Publication of Abstracts for ASCO 2023 Annual Meeting
-
Immutep Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer
-
Immutep Announces Promising New Clinical Data from Triple Combination Therapy in INSIGHT-003 Trial
-
Immutep (IMMP) Receives Positive Feedback from FDA on Eftilagimod Alpha
-
Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer
-
Immutep to Participate in the JMP Securities Life Sciences Conference
-
Immutep Announces KOL Event Focused on Eftilagimod Alpha in Non-Small Cell Lung Cancer and Head & Neck Squamous Cell Carcinoma
-
Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®
-
Immutep Quarterly Activities Report
-
Immutep Announces Presentation of New TACTI-002 Data at the 2023 ASCO Annual Meeting
-
Immutep (IMMP) Appoints Florian Vogl as Chief Medical Officer
-
Immutep Appoints Dr. Florian Vogl as Chief Medical Officer
-
Immutep Announces Initiation of Investigator-Initiated Phase II Trial in Soft Tissue Sarcoma in Neoadjuvant Setting
-
Immutep (IMMP) Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023
-
Immutep Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023
-
Immutep Announces Expansion of Triple Combination Therapy in 1st Line Non-Small Cell Lung Cancer
-
Immutep Announces Abstract Accepted for Mini Oral Presentation at ESMO’s European Lung Cancer Congress 2023
-
Immutep Limited (IMMP) received Notice of Allowance for US patent related to cancer treatment
-
Immutep Announces Initiation of Phase II/III Trial for Eftilagimod Alpha plus Paclitaxel in Metastatic Breast Cancer
-
Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC
-
Immutep Quarterly Activities Report
-
Immutep Achieves 50% Enrollment Milestone in Randomised Phase IIb TACTI-003 Trial for First Line Head & Neck Cancer
-
Immutep (IMMP) Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy
-
Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer
-
Immutep Successfully Achieves Commercial Scale in Manufacturing of Eftilagimod Alpha
-
Immutep Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease
-
Immutep to Participate in The JMP Securities Hematology and Oncology Summit
-
Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, an
-
Immutep (IMMP) Enters Second Collaboration With Pfizer & Merck KG
-
Immutep Receives Australian R&D Tax Incentive
-
Immutep (IMMP) Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC
Back to IMMP Stock Lookup
